Loading…
← CockpitCompetitor Analysis › 2335.HK Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class HOpen in the cockpit ↗

Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H2335.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Mkt cap
$715M
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$17.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · HKDHK$19.00
1D-8.0%
1W-10.9%
1M+8.3%
3M-37.9%
6Mn/a
YTDn/a
1Yn/a
ATR %18.8%
52w lowhigh57.8% off high

What Shaanxi Micot Pharmaceutical Technology does

Employees: 121

Shaanxi Micot Pharmaceutical Technology at a glance

Size Shaanxi Micot Pharmaceutical Technology (2335.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $715M, the 663rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.00 on 18 Nov 2026.

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Shaanxi Micot Pharmaceutical Technology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueHK$0HK$0HK$0HK$0
Revenue growth————
Gross profit-HK$6.97M-HK$7.13M-HK$9.09M-HK$9.55M
EBITDA-HK$291M-HK$159M-HK$127M-HK$106M
Net income-HK$409M-HK$198M-HK$168M-HK$207M
Free cash flowHK$12.7M-HK$167M-HK$108M-HK$111M
Capital expenditureHK$19.1MHK$18.4MHK$1.41MHK$2.27M
Total debtn/aHK$1.35BHK$49.5MHK$850M

Quarterly statements and history in the cockpit →

Shaanxi Micot Pharmaceutical Technology competitors and peer comparison

How Shaanxi Micot Pharmaceutical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shaanxi Micot Pharmaceutical Technology against its 20 peers (data as of 18 Nov 2026)
Measure2335.HKPeer medianRank in peer set
1-month return+8.3%-7.1%4th highest of 21
Distance from 52-week high-57.8%-45.9%5th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a

Questions

Which companies are Shaanxi Micot Pharmaceutical Technology's closest peers?
The cockpit's peer set: Attovia Therapeutics (ATTO), Solid Biosciences (SLDB), R&G PharmaStudies (301333.SZ), Apnimed (APMD), Prime Medicine (PRME), Beijing SL Pharmaceutical (002038.SZ), Aura Biosciences (AURA), Anhui Wanbang Pharmaceutical Technology (301520.SZ).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.